Bank of America’s NKGen Biotech, Inc. Common Stock NKGN Stock Holding History

Bank of America’s Portfolio NKGN Stock Details NKGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-102	Closed	-$67	–	8671
2024 Q4	$67	Sell	102 -4	-4%	-$2	﹤0.01%	7819
2024 Q3	$40	Buy	106 +56	+112%	+$50	﹤0.01%	7872
2024 Q2	$64	Buy	+50	New	+$70	﹤0.01%	7797
2022 Q2	–	Sell	-349,900	Closed	-$3.39M	–	8481
2022 Q1	$3.39M	Hold	349,900	–	–	﹤0.01%	4028
2021 Q4	$3.38M	Buy	349,900 +100,000	+40%	+$973K	﹤0.01%	4038
2021 Q3	$2.42M	Buy	+249,900	New	+$2.44M	﹤0.01%	4259

Other funds holding NKGN

Diametric Capital Boston, Massachusetts $385M AUM 31.7% 1-Year Est. Return

UOC

University of Chicago Chicago, Illinois $323M AUM 14.1% 1-Year Est. Return

FTUS

Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return

Bank of America's NKGN Position: Q1 2025 in Review

Bank of America sold out of NKGen Biotech, Inc. Common Stock (NKGN) in Q1 2025, closing a stake of 102 shares — an estimated $67 sold.

Bank of America first reported a position in NKGN in Q3 2021 and held it in 6 quarters. The position peaked at $3.39M in Q1 2022. 3 funds tracked by Wall St. Rank hold NKGN as of Q1 2025.

Bank of America reported no remaining NKGen Biotech, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
Bank of America sold 102 NKGen Biotech, Inc. Common Stock shares in Q1 2025, an estimated $67.
Bank of America first reported a position in NKGen Biotech, Inc. Common Stock in Q3 2021 and held it in 6 quarters.
Bank of America's NKGen Biotech, Inc. Common Stock position peaked at $3.39M in Q1 2022.
3 funds tracked by Wall St. Rank held NKGen Biotech, Inc. Common Stock as of Q1 2025.

Based on Bank of America's 13F filing for Q1 2025, filed 15 May 2025.